Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials

In the context of the current coronavirus disease 2019 (COVID-19) pandemic, there is no direct evidence to support any preferred biologic therapy for psoriasis However, known safety profile of different classes of biologic therapies as well as individual risk factors for infections must be considered Here, we report incidence rates of respiratory or viral infections through 5 years among patients with moderate-to-severe plaque psoriasis who were treated with the interleukin (IL)-23p19 inhibitor tildrakizumab from reSURFACE 1 and reSURFACE 2 phase III trials